The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
The DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
After a pause of nearly 40 years in research into the effects of psychedelic drugs, recent advances in our understanding of the neurobiology of psychedelics, such as lysergic acid diethylamide (LSD), psilocybin and ketamine have led to renewed interest in the clinical potential of psychedelics in the treatment of various psychiatric disorders. Recent behavioural and neuroimaging data show that psychedelics modulate neural circuits that have been implicated in mood and affective disorders, and can reduce the clinical symptoms of these disorders. These findings raise the possibility that research into psychedelics might identify novel therapeutic mechanisms and approaches that are based on glutamate-driven neuroplasticity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It has been suggested that the persisting therapeutic effects of psychedelics are attributable to a similar biological mechanism (39, 40).”
From Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. (2021) · cites this paper as [39]
Citations
Cites
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 1×
“5 mg per kg), and this effect was sustained for at least 72 hour”
BackgroundA randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330 · cited 1×
“Dissociative anaesthetics mimic the positive and the negative symptoms (social withdrawal and apathy) of schizophrenia through antagonism at NMDA ( N -methyl- D -aspartate) glutamate receptor”
BackgroundMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793 · cited 1×
“Systemic administration of non-competitive NMDA antagonists, such as ketamine, PCP and MK-801 (also known as dizocilpine), in rats markedly increases glutamate release in the mPF”
BackgroundDavis, H. S. (1966) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1966.03100200106038 · Cited by 1,719
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 1×
“and was rated as among the most personally meaningful experience”
Background(1990) · Springer eBooks · doi:10.1007/978-3-642-74034-3 · Cited by 1,523
Anis, N. A., Berry, S. C., Burton, N. R., & Lodge, D. (1983) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1983.tb11031.x · Cited by 1,399
(2009) · Elsevier eBooks · doi:10.1016/c2009-1-03742-3 · Cited by 1,308
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231 · cited 1×
“These effects are probably due to a blockade of NMDA receptors on GABA (γ-aminobutyric acid)-ergic interneuron”
Background
Research works printed but not linked: 6
- Hofmann, A. in Chemical Constitution and Pharmacodynamic Actions (ed. Burger, A.) 169–235 (M.Dekker, New York, 1968).
- Dittrich, A. in 50 Years of LSD. Current Status and Perspectives of Hallucinogens (eds Pletscher, A. & Ladewig, D.) 101–118 (Parthenon, New York, 1994).
- Hoffer, A. in The Uses and Implications of Hallucinogenic Drugs (eds Aaronson, B. & Osmond, H.) 357–366 (Hogarth Press, London, 1970).
- Leuner, H. in 50 Years of LSD: Current Status and Perspectives of Hallucinogen Research (eds Pletscher, A. & Ladewig, D.) 175–189 (Parthenon, New York, 1994).
- Crocket, R., Sandison, R. A. & Walk, A. in Proc. R. Med–Psychol. Assoc. (Lewis & Co., London, 1963).
- Leuner H. in Ethnopsychotherapie (eds Dittrich, A. & Scharfetter, C.) 151–161 (Enke, Stuttgard, 1987)
Cited by
Items 301–400 of 721
Serotonergic neuromodulation of synaptic plasticity
Higa, G. S. V., Viana, F. J. C., Francis-Oliveira, J., Cruvinel, E., Franchin, T. S., Marcourakis, T., Ulrich, H., & De Pasquale, R. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110036 · Cited by 29
Fox, K. C. R., Girn, M., Parro, C., & Christoff, K. (2018) · Cambridge University Press eBooks · doi:10.1017/9781316556238.007 · Cited by 30
Steiner, J., Schiltz, K., Bernstein, H., & Bogerts, B. (2015) · CNS Drugs · doi:10.1007/s40263-015-0233-3 · Cited by 29
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Banushi, B., & Polito, V. (2023) · Biology · doi:10.3390/biology12111380 · Cited by 37
“Both classes of drugs stimulate AMPARs by increasing extracellular glutamate levels and elevate BDNF levels in brain areas implicated in depression [22,145,220,222,224,235–238], facilitating the adaptive rewiring of pathological neurocircuitry and explaining their sustained therapeutic effects [52].”
BackgroundInfluentialEfficacy and Safety of Psychedelics in Treating Anxiety Disorders
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 34
“23,38 Since then, studies have been conducted into the therapeutic efficacy and safety profile of specific psychedelics for various conditions such as anxiety, posttraumatic stress disorder, depression, smoking, and treatment-resistant obsessive-compulsive disorder.”
BackgroundRush, B. R., Marcus, O., García, S., Loizaga-Velder, A. K., Loewinger, G. C., Spitalier, A., & Mendive, F. M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.659644 · Cited by 36
Oña, G., Berrada, A., & Bouso, J. C. (2021) · Transcultural Psychiatry · doi:10.1177/13634615211038416 · Cited by 35
“Other potential mechanisms include neuroendocrine (Schindler et al., 2018), anti-inflammatory (Flanagan & Nichols, 2018), and glutamatergic actions (Vollenweider & Kometer, 2010).”
BackgroundAyahuasca as Antidepressant? Psychedelics and Styles of Reasoning in Psychiatry
Anderson, B. T. (2012) · Anthropology of Consciousness · doi:10.1111/j.1556-3537.2012.01056.x · Cited by 43
How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy
Orsolini, L., Chiappini, S., Papanti, D., Latini, R., Volpe, U., Fornaro, M., Tomasetti, C., Vellante, F., & Berardis, D. D. (2020) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.2728 · Cited by 37
“…the fronto-cortical glutamate network activation due to 5-HT2A receptor agonism, may be responsible of its antidepressive, anxiolytic, and antiaddictive effects (Baumeister et al., 2014; Bogenschutz & Johnson, 2016; Bogenschutz & Pommy, 2012; Fortunato et al., 2009; Vollenweider & Kometer, 2010).”
BackgroundDose-response relationships of LSD-induced subjective experiences in humans
Hirschfeld, T., Prugger, J., Majić, T., & Schmidt, T. T. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01588-2 · Cited by 32
Rapid-acting antidepressant drugs modulate affective bias in rats
Hinchcliffe, J. K., Stuart, S. A., Wood, C. M., Bartlett, J. M., Kamenish, K., Arban, R., Thomas, C. W., Selimbeyoglu, A., Hurley, S., Hengerer, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adi2403 · Cited by 31
“Ketamine, psilocybin and scopolamine target different receptors but there is convergence in their effects at the cellular and network level where they facilitate glutamate-mediated neurotransmission and acutely increase cortical excitability (36–39).”
Psilocybin for the treatment of Alzheimer’s disease
Zheng, S., Ma, R., Yang, Y., & Li, G. (2024) · Frontiers in Neuroscience · doi:10.3389/fnins.2024.1420601 · Cited by 28
Virtual Reality as a Moderator of Psychedelic-Assisted Psychotherapy
Sekula, A. D., Downey, L. A., & Puspanathan, P. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.813746 · Cited by 34
“Conversely, resisting the difficult experience could obstruct the therapy’s beneficial effects, impact the resolution of the issue and catalyze the progression from a challenging experience to an adverse effect (Vollenweider and Kometer, 2010).”
BackgroundKantonen, O., Laaksonen, L., Alkire, M. T., Scheinin, A., Långsjö, J., Kallionpää, R., Kaisti, K. K., Radek, L., Johansson, J. J., Laitio, T. T., et al. (2023) · Journal of Neuroscience · doi:10.1523/jneurosci.2339-22.2023 · Cited by 28
“The dissociative state characteristic of (S-)ketamine is likely caused by preferential antagonism of NMDA receptors in GABAergic interneurons leading to disinhibition of excitatory pyramidal neurons (Homayoun and Moghaddam, 2007; Vollenweider and Kometer, 2010).”
BackgroundGass, N., Becker, R., Sack, M., Schwarz, A. J., Reinwald, J., Cosa‐Linan, A., Zheng, L., von Hohenberg, C. C., Inta, D., Meyer‐Lindenberg, A., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4823-2 · Cited by 31
“On the one hand, this might be related to the effects of audiovisual synesthesia, acoustic alterations, and changes of visual perception under ketamine (Vollenweider and Kometer 2010).”
BackgroundConvergent evolution of psilocybin biosynthesis by psychedelic mushroomsPreprint
Awan, A. R., Winter, J. M., Turner, D., Shaw, W. M., Suz, L. M., Bradshaw, A. J., Ellis, T., & Dentinger, B. T. M. (2018) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/374199 · Cited by 35
“Given the proven interaction of Diptera with psilocybin-producing mushrooms, the known neurological effects of psilocybin on humans 29,30 , and the fact that orthologues of the psilocybin cluster genes are present in the termite mutalist fungus Fibularhizoctonia sp. 6 , we suggest the alternative…”
Storm on predictive brain: A neurocomputational account of ketamine antidepressant effect
Bottemanne, H., Berkovitch, L., Gauld, C., Balcerac, A., Schmidt, L., Mouchabac, S., & Fossati, P. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105410 · Cited by 33
Kimmey, B. A., Ostroumov, A., & Dani, J. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911446116 · Cited by 26
Schmidt, T. T., Jagannathan, N., Ljubljanac, M., Xavier, A., & Nierhaus, T. (2020) · Scientific Reports · doi:10.1038/s41598-020-75019-3 · Cited by 38
Bernal, A. M. O., Raison, C. L., Lancelotta, R., & Davis, A. K. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1049643 · Cited by 35
Tófoli, L. F., & de Araújo, D. B. (2016) · International review of neurobiology · doi:10.1016/bs.irn.2016.06.005 · Cited by 43
“A more rapid effect of psychedelics may be associated with BDNF increases primarily in cortical pyramidal cells of layer V via a mechanism involving stimulation of 5HT 2A receptors (Vollenweider & Kometer, 2010).”
Larrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 34
“BDNF: brain-derived neurotrophic factor; DLPFC”
Szpręgiel, I., & Bysiek, A. (2024) · Pharmacological Reports · doi:10.1007/s43440-024-00660-y · Cited by 32
“It has been proposed that psilocybin exerts its antidepres - sant effects by deactivating or normalizing the hyperexcit - ability of the medial prefrontal cortex (mPFC) [ 17 , 20, 21 ].”
A neuroscientific model of near-death experiences
Martial, C., Fritz, P., Gosseries, O., Bonhomme, V. L., Kondziella, D., Nelson, K. R., & Lejeune, N. (2025) · Nature Reviews Neurology · doi:10.1038/s41582-025-01072-z · Cited by 40
Padawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 36
“Psychedelic-induced hallucinations depend on activity of serotonin (5-HT) receptors, primarily at the 5-HT 2A receptor (5-HT 2A R) 10 and also elicit dose-dependent vasoactive effects 11,12 .”
New psychoactive substances—Synthetic stimulants
Varì, M. R., Pichini, S., Giorgetti, R., & Busardò, F. P. (2018) · Wiley Interdisciplinary Reviews Forensic Science · doi:10.1002/wfs2.1197 · Cited by 30
Psychedelic therapy in depression and substance use disorders
Korkmaz, N. D., Çıkrıkçılı, U., Akan, M., & Yücesan, E. (2024) · European Journal of Neuroscience · doi:10.1111/ejn.16421 · Cited by 32
“Additionally, it has been shown that they also demonstrate potent agonist effects against 5-HT 2A R, a G-protein-coupled receptor (GPCR) highly effective in anxiolytic and antidepressant treatments (Vollenweider & Kometer, 2010).”
Wojtas, A., Bysiek, A., Wawrzczak‐Bargieła, A., Maćkowiak, M., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010100 · Cited by 30
“The regulation of mesocortical DA by psilocybin may involve cortical glutamatergic fibers expressing 5-HT2A receptors projecting to the nucleus accumbens or ventral tegmental area (VTA), thus indirectly increasing DA release.”
BackgroundSocial inequality, scientific inequality, and the future of mental illness
Dean, C. E. (2017) · Philosophy Ethics and Humanities in Medicine · doi:10.1186/s13010-017-0052-x · Cited by 32
“Interest is growing in the use of hallucinogens [75], whole body hyperthermia [76], and even opiates [77] for treatment-resistant major depression.”
BackgroundPsychedelic drugs for psychiatric disorders
da Costa, S. C., Oesterle, T., Rummans, T. A., Richelson, E., & Gold, M. S. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120332 · Cited by 37
Sarasso, P., Billeci, M., Ronga, I., Raffone, F., Martiadis, V., & Petta, G. D. (2024) · Psychopathology · doi:10.1159/000539714 · Cited by 32
Psychedelic-assisted therapies: The past, and the need to move forward responsibly
Gardner, J., Carter, A., O’Brien, K., & Seear, K. (2019) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2019.05.019 · Cited by 34
Psilocybin mitigates the cognitive deficits observed in a rat model of Fragile X syndrome
Buzzelli, V., Carbone, E., Manduca, A., Schiavi, S., Feo, A., Perederiy, J. V., Ambert, K. H., Hausman, M., & Trezza, V. (2023) · Psychopharmacology · doi:10.1007/s00213-022-06286-3 · Cited by 22
“Microdoses appear to be more beneficial compared to standard doses as they do not seem to give perceptive alterations (Ona and Bouso 2020; Vollenweider and Kometer 2010).”
BackgroundInfluentialAboharb, F., Davoudian, P. A., Shao, L.-X., Liao, C., Rzepka, G. N., Wojtasiewicz, C., Indajang, J., Dibbs, M., Rondeau, J. A., Sherwood, A. M., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-56850-6 · Cited by 27
Howland, R. H. (2016) · Journal of Psychosocial Nursing and Mental Health Services · doi:10.3928/02793695-20160616-09 · Cited by 25
Rostral Anterior Cingulate Thickness Predicts the Emotional Psilocybin Experience
Lewis, C. R., Preller, K. H., Braden, B. B., Riecken, C., & Vollenweider, F. X. (2020) · Biomedicines · doi:10.3390/biomedicines8020034 · Cited by 23
Self-citationInter-individual variability in neural response to low doses of LSD
Hutten, N. R. P. W., Quaedflieg, C. W. E. M., Mason, N. L., Theunissen, E. L., Liechti, M. E., Duthaler, U., Kuypers, K. P. C., Bonnelle, V., Feilding, A., & Ramaekers, J. G. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03013-8 · Cited by 25
“At higher doses, psychedelics have been suggested to increase bottom-up processing of sensory information [63, 64] and relax top-down control [65] in healthy volunteers that may lead to a sensory overload and a subsequent breakdown of sensory integration as re fl ected by impaired MMN [64].”
BackgroundPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodríguez, C. I., Kalin, N. H., & McDonald, W. M. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19104 · Cited by 28
Glavonic, E., Mitić, M., & Adžić, M. (2022) · Journal of Neuroscience Research · doi:10.1002/jnr.25017 · Cited by 24
“Vollenweider and Kometer (2010) proposed a model in which psilocybin increases extracellular glutamate levels in the prefrontal cortex through the activation of postsynaptic 5- HT2A receptors, leading to enhanced stimulation of both AMPARs and NMDARs (De Gregorio et al., 2018).”
BackgroundDemin, K. A., Kupriyanova, O. V., Shevyrin, V. A., Derzhavina, K. A., Krotova, N. A., Ilyin, N. P., Kolesnikova, T. O., Galstyan, D. S., Kositsyn, Y. M., Khaybaev, A.-A. S., et al. (2022) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.2c00123 · Cited by 23
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Jones, G. M., Arias, D., & Nock, M. K. (2022) · Scientific Reports · doi:10.1038/s41598-022-25658-5 · Cited by 24
Can Psychedelic Drugs Attenuate Age-Related Changes in Cognition and Affect?
Aday, J. S., Bloesch, E. K., & Davoli, C. C. (2019) · Journal of Cognitive Enhancement · doi:10.1007/s41465-019-00151-6 · Cited by 27
The philosophy of psychedelic transformation
Letheby, C. (2017) · Adelaide Research & Scholarship (AR&S) (University of Adelaide) · doi:10.4225/55/5900324d2ad60 · Cited by 18
“It has been suggested that classic psychedelics and dissociative anaesthetics (such as ketamine) may share a common therapeutic mechanism in ultimately targeting glutamate-driven neuroplasticity (Vollenweider and Kometer 2010).”
BackgroundInfluentialModern neuroimaging in psychiatry: Towards the integration of functional and molecular information
Linden, D. E. J., & Thome, J. (2011) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2011.598713 · Cited by 24
“If drugs are used that have relatively specifi c neurochemical effects, for example levodopa or haloperidol as agonist/ antagonist of the dopaminergic system or psychedelic drugs as agonists at serotonin receptors (Vollenweider and Kometer 2010), inferences on the pathways (e.”
BackgroundSystematic Review of Interventions for Demoralization in Patients With Cancer
Wang, Y., Sun, H., Ji, Q., Wei, J., & Zhu, P. (2023) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0000000000001615 · Cited by 22
“Serotonergic psychedelics (e.g., psilocybin) alter consciousness by activating serotonin 2A (5HT2A) receptors (Vollenweider and Kometer, 2010).”
BackgroundNot in the drug, not in the brain: Causality in psychedelic experiences from an enactive perspective
Meling, D., & Scheidegger, M. (2023) · Frontiers in Psychology · doi:10.3389/fpsyg.2023.1100058 · Cited by 24
“In addition to their 5-HT2A partial agonism, classic psychedelics have been shown to increase levels of glutamate (Vollenweider and Kometer, 2010) and oxytocin (Holze et al.”
BackgroundArtigas, F., Celada, P., & Bortolozzi, A. A. (2018) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.01.005 · Cited by 23
“The reasons for these discrepancies are poorly known and may involve species differences (e.g., Vollenweider and Kometer, 2010) as well as a different selectivity of ketamine for NMDA-R in different cellular types at the various doses and routes used.”
BackgroundResultInfluentialSchindler, E. A. D., Dave, K. D., Smolock, E. M., Aloyo, V. J., & Harvey, J. A. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.12.002 · Cited by 24
“, 2011), implicates complex interactions, such as genetic effects or perhaps even changes in neurocircuitry (Passie et al., 2008; Vollenweider and Kometer, 2010).”
BackgroundMolecular and Medical Aspects of Psychedelics
Wojtas, A., & Gołembiowska, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010241 · Cited by 27
“Contrary to LSD, which binds to D2 receptors, psilocybin exhibits no affinity for dopamine D2 receptors [92,93].”
BackgroundSolaja, I., Haldane, K., Mason, N. L., Weiss, B., Xu, X., Xu, M., Nikolin, S., Jayasena, T., Millard, M., Brett, J., et al. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105570 · Cited by 23
Kaldewaij, R., Salamone, P., Enmalm, A., Östman, L., Pietrzak, M., Karlsson, H., Löfberg, A., Gauffin, E., Samuelsson, M., Gustavson, S., et al. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01906-2 · Cited by 26
“Similar to other psychedelic drugs, ketamine induces an altered state of consciousness, but its effect on disembodiment is more pronounced compared to, for example, psilocybin [45].”
BackgroundLucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 23
“Psychedelics share the property of producing intense experiences characterized by altered cognitive, emotional, and sensory processing as well as dramatic changes in brain connectivity [147] and the induction of neuroplasticity [148,149].”
Harmony, Perspective, and Triadic Cognition
Cook, N. D. (2011) · Cambridge University Press eBooks · doi:10.1017/cbo9780511844423 · Cited by 21
The antipsychotic landscape: dopamine and beyond
Morrison, P. D., & Murray, R. M. (2018) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125317752915 · Cited by 19
Effects of psychedelics on neurogenesis and broader neuroplasticity: a systematic review
da Cruz, R. V. L., Leão, R. N., & Moulin, T. C. (2024) · Molecular Medicine · doi:10.1186/s10020-024-01013-4 · Cited by 22
“Despite the consensus that those initial studies have several shortcomings regarding scientific or statistical rigor (Vollenweider and Kometer, 2010), they were the first to suggest the clinical use of these substances, which has been supported by recent data from both animal and human studies…”
A proposal to evaluate mechanistic efficacy of hallucinogens in addiction treatment
Burdick, B. V., & Adinoff, B. (2013) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2013.811513 · Cited by 18
“Presently, no ongoing trials involving peyote, mescaline, ayahuasca, dimethyltryptamine (DMT) or ibogaine are reported by governmental agencies at ClinicalTrials.gov, despite prior favorable findings (7–9,16,26,31).”
BackgroundInfluentialRuban, A., & Kołodziej, A. (2018) · Neuropsychiatria i Neuropsychologia · doi:10.5114/nan.2018.81249 · Cited by 23
Scheidegger, M. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_3 · Cited by 23
Perceptual pathways to hallucinogenesis
Sheldon, A. D., Kafadar, E., Fisher, V., Greenwald, M. S., Aitken, F., Negreira, A. M., Woods, S. W., & Powers, A. R. (2022) · Schizophrenia Research · doi:10.1016/j.schres.2022.02.002 · Cited by 19
Bifone, A., & Gozzi, A. (2012) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2012.724057 · Cited by 18
Calder, A. E., Hase, A., & Hasler, G. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02830-z · Cited by 25
Effects of Hallucinogens on Neuronal Activity
Lladó-Pelfort, L., Celada, P., Riga, M. S., Troyano‐Rodriguez, E., Santana, N., & Artigas, F. (2017) · Current topics in behavioral neurosciences · doi:10.1007/7854_2017_473 · Cited by 19
“…diethylamide (LSD), 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), mescaline and psilocybin, produce hallucinogenic effects, altering perception, thought, emotion and mood in a manner that is similar to endogenous psychosis (Glennon 1991, 1994; Nichols 2004; Vollenweider and Kometer 2010).”
BackgroundOut of the box: A psychedelic model to study the creative mind
Kuypers, K. P. C. (2018) · Medical Hypotheses · doi:10.1016/j.mehy.2018.03.010 · Cited by 24
Cellular rules underlying psychedelic control of prefrontal pyramidal neuronsPreprint
Ekins, T. G., Brooks, I. A. W., Kailasa, S., Rybicki-Kler, C., Jedrasiak‐Cape, I., Donoho, E., Mashour, G. A., Rech, J. C., & Ahmed, O. J. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.10.20.563334 · Cited by 24
The entropic heart: Tracking the psychedelic state via heart rate dynamicsPreprint
Rosas, F. E., Mediano, P. A. M., Timmermann, C., Luppi, A. I., Candia‐Rivera, D., Abbasi-Asl, R., Gazzaley, A. H., Kringelbach, M. L., Muthukumaraswamy, S. D., Bor, D., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.07.566008 · Cited by 23
“…[DMT]) act primarily on the 5-HT 2A receptor, and the atypical psychedelic ketamine exerts its effects primarily via NMDA receptor antagonism (25), they both reliably disrupt important markers of spontaneous brain function at wakeful rest evidenced, e.g., by reductions of alpha power and…”
BackgroundGill, H., Puramat, P., Patel, P., Gill, B., Marks, C. A., Rodrigues, N. B., Castle, D., Cha, D. S., Mansur, R. B., Rosenblat, J. D., et al. (2022) · Psychiatry Research · doi:10.1016/j.psychres.2022.114577 · Cited by 16
“For example, positron emission tomography (PET) studies with healthy participants indicate increased neuronal activity in the prefrontal cortex and limbic regions following moderate doses of psilocybin (Vollenweider & Kometer, 2010).”
BackgroundVorobyeva, N. S., & Kozlova, A. A. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.927984 · Cited by 24
Guglielmo, R., & Hasler, G. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104906 · Cited by 17
Converging theories on dreaming: Between Freud, predictive processing, and psychedelic research
Koslowski, M., Haas, M.-P. D., & Fischmann, T. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1080177 · Cited by 26
“, dysfunction of thalamic gating, leading to very similar conclusions for subjective experience and brain functioning in the psychedelic state (Vollenweider and Kometer, 2010; Preller and Vollenweider, 2018).”
BackgroundKetamine modifies mood through mTOR
Welberg, L. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2916 · Cited by 16
Kelly, D. F., Heinzerling, K. G., Sharma, A., Gowrinathan, S., Sergi, K., & Mallari, R. J. (2022) · Neurosurgery · doi:10.1227/neu.0000000000002275 · Cited by 17
Synergistic psychedelic - NMDAR modulator treatment for neuropsychiatric disorders
Heresco‐Levy, U., & Lerer, B. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02312-8 · Cited by 15
“A complex interplay between serotonergic and glutamatergic systems in prefrontal circuits may underlie the therapeutic effects of psilocybin [29].”
Aepfelbacher, J., Panny, B., & Price, R. B. (2024) · Biological Psychiatry Global Open Science · doi:10.1016/j.bpsgos.2024.100316 · Cited by 18
Psychedelics and schizophrenia: a double-edged sword
Sapienza, J., Martini, F., Comai, S., Cavallaro, R., Spangaro, M., Gregorio, D. D., & Bosia, M. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02743-x · Cited by 20
“Psychedelics exert their pharmacological effects primarily through the 5-HT system, acting as agonists or partial agonists of the 5-HT2A receptor [46, 50, 51].”
Ruffini, G., Castaldo, F., Lopez-Sola, E., Sanchez-Todo, R., & Vohryzek, J. (2024) · Entropy · doi:10.3390/e26110953 · Cited by 25
Psychedelics align brain activity with context
Stoliker, D., Novelli, L., Khajehnejad, M. A., Biabani, M., Greaves, M. D., Barta, T., Williams, M., Chopra, S., Bazin, O., Simonsson, O., et al. (2026) · Nature · doi:10.1038/s41586-026-10910-z · Cited by 26
“These subscales were analysed post hoc to assess patterns of covariation (Vollenweider and Kometer, 2010), identifying groups of subscales that showed high intercor-relations in our sample (Fig.”
5-HT2A Receptors and BDNF Regulation: Implications for Psychopathology
Jaggar, M., & Vaidya, V. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-70474-6_17 · Cited by 19
Effectiveness of Psilocybin on Depression: A Qualitative Study
Alshaikhli, H., Al-Naggar, R. A., & Erlam, G. D. (2021) · Electronic Journal of General Medicine · doi:10.29333/ejgm/10862 · Cited by 23
Madrid-Gambín, F., Gomez‐Gómez, À., Busquets-García, A., Haro, N., Marco, S., Mason, N. L., Reckweg, J. T., Mallaroni, P., Kloft, L., van Oorsouw, K. I. M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112845 · Cited by 18
“In addition, agonism at 5-HT2A receptors, which are a direct target of DMT, may modulate glutamatergic neurotransmission [41], leading to anxiolytic and antidepressant effects and enhancements of neuroplasticity [2,9,26,77].”
BackgroundAskariyan, K., Joghataei, M. T., Dehghan, S., Nohesara, S., Rihipour, L., Mohammadi, M. H., & Ahmadirad, N. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111461 · Cited by 15
Wang, K., Sun, Y., Nava, B., Sampiere, L., & Jacobs, R. J. (2023) · Cureus · doi:10.7759/cureus.37450 · Cited by 18
“Findings from studies suggest that psilocybin may be effective in producing fast-acting and long-lasting antidepressant effects in patients with major depressive disorder [8].”
BackgroundNatural psychedelics in the treatment of depression; a review focusing on neurotransmitters
Jahanabadi, S., Amiri, S., Karkeh-abadi, M., & Razmi, A. (2023) · Fitoterapia · doi:10.1016/j.fitote.2023.105620 · Cited by 16
Wong, S., Yu, A. Y., Fabiano, N., Finkelstein, O., Pasricha, A., Jones, B. D. M., Rosenblat, J. D., Blumberger, D. M., Mulsant, B. H., & Husain, M. I. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2251133 · Cited by 17
“This has led to a growing interest in alternative treatments including psychedelic drugs (Vollenweider and Kometer 2010).”
Promising new pharmacological targets for depression: The search for efficacy
Tsugiyama, L. E., de Moraes, R. C. M., Moraes, Y. A. C., & de Oliveira, J. F. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103804 · Cited by 16
Orlowski, P., Hobot, J., Ruban, A., Szczypiński, J., & Bola, M. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231216322 · Cited by 15
“…regulation (Orłowski et al., 2022; Tang et al., 2016); also, both have therapeutic potential for mood disorders (Marchand, 2012; Pascoe et al., 2021; Vollenweider and Kometer, 2010) and have similar effects on neuronal activity, such as reduction of activity in the default mode network (Gattuso et…”
BackgroundVelit-Salazar, M. R., Shiroma, P. R., & Cherian, E. (2024) · Brain Sciences · doi:10.3390/brainsci14030248 · Cited by 15
“These psychedelics may additionally produce direct agonism of 5-HT 1A , 5-HT 2C , 5-HT 7 , and dopaminergic D 2 receptors [6].”
BackgroundDowney, A. E., Chaphekar, A. V., Woolley, J. D., & Raymond‐Flesch, M. (2024) · Journal of Eating Disorders · doi:10.1186/s40337-024-01005-z · Cited by 17
“Once ingested, psilocybin is rapidly broken down to the active metabolite psilocin [9, 10, 12] which likely exerts its psychedelic effects through agonism at 5-HT 2A G-protein coupled receptors [13, 14].”
BackgroundGlynos, N. G., Huels, E. R., Groenhout, T., Raghu, A., Nelson, A. G., Kim, Y., Zeid, A. M., Liu, T., Mashour, G. A., Kennedy, R. T., et al. (2025) · Journal of Neuroscience · doi:10.1523/jneurosci.0742-24.2025 · Cited by 21
Multiple facets of serotonergic modulation
Beyeler, A., Ju, A., Chagraoui, A., Cuvelle, L., Teixeira, M., Giovanni, G. D., & Deurwaerdère, P. D. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.02.002 · Cited by 16
Psilocybin and palliative end-of-life care
Shelton, R. C., & Hendricks, P. S. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675764 · Cited by 15
“How does psilocybin produce these benefits? Possible mechanisms of action may include increases in glial cell line– derived neurotrophic factor and brain-derived neurotrophic factor, downregulation of 5HT2A receptors, alterations in pyramidal cell dendritic spine organization, and normalization of the default mode net…”
BackgroundNagels, A., Cabanis, M., Oppel, A., Kirner-Veselinovic, A., Schales, C., & Kircher, T. T. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.270 · Cited by 16
“Based on the literature, personal exchange with Franz Vollenweider, Zurich (Vollenweider, 1998; Vollenweider and Geyer, 2001; Vollenweider and Kometer, 2010; Vollenweider et al, 1997a, b; Vollenweider et al, 2000), and own pilot experiments before our scanning study, we used S-ketamine in a dose of 0.”
MethodInfluentialSchmidt, T. T., & Majić, T. (2016) · Springer eBooks · doi:10.1007/978-3-642-55214-4_65-1 · Cited by 15
Arias, H. R., Rudin, D., Hines, D. J., Contreras, A., Gulsevin, A., Manetti, D., Anouar, Y., Deurwaerdère, P. D., Meiler, J., Romanelli, M. N., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176329 · Cited by 18
“Visual hallucinations caused by serotonergic hallucinogens, such as psilocybin and LSD, are primarily mediated through 5-HT 2A receptors (Nichols, 2004; Vollenweider and Kometer, 2010).”
Psychedelic Therapy: A Primer for Primary Care Clinicians—Ketamine
Evans, V. D., Arenas, A., Shinozuka, K., Tabaac, B. J., Beutler, B. D., Cherian, K. N., Fasano, C., & Muir, O. S. (2024) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001721 · Cited by 19
Pain and Perception: Exploring Psychedelics as Novel Therapeutic Agents in Chronic Pain Management
Strand, N. H., Whitney, M. A., Johnson, B. W., Dunn, T., Attanti, S., Maloney, J. A., Misra, L., Gomez, D., Viswanath, O., Emami, E., et al. (2025) · Current Pain and Headache Reports · doi:10.1007/s11916-024-01353-0 · Cited by 15
“Ketamine is a dissocia - tive anesthetic and, unlike LSD and psilocybin, it operates primarily through the glutamatergic system, resulting in a markedly different phenomenological experience often characterized by reduced psychotropic immersion [18].”
Adebo, M., Bonnet, M., Laouej, O., Defaix, C., McGowan, J. C., Butlen‐Ducuing, F., David, D. J. P., Poupon, E., Tritschler, L., & Gardier, A. M. (2025) · Fundamental and Clinical Pharmacology · doi:10.1111/fcp.70038 · Cited by 14
“Its impact on glutamatergic signaling via mGluR2–3 glutamate receptors could also promote neuroplasticity via an activation of BDNF/TrkB/mTOR signaling cascade, as ketamine [22, 30, 70].”
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
Jacobs, E. (2020) · Journal of Psychedelic Studies · doi:10.1556/2054.2020.00128 · Cited by 19
Neurobiology of the Effects of Psilocybin in Relation to Its Potential Therapeutic Targets
Tylš, F., Páleníček, T., & Horáček, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00073-x · Cited by 15
Leptourgos, P., Bouttier, V., Denève, S., & Jardri, R. (2021) · PsyArXiv (OSF Preprints) · doi:10.1016/j.neubiorev.2022.104593 · Cited by 17
Metadata
- Authors
- Vollenweider, F. X., & Kometer, M.
- Affiliations
- University of Zurich (CH)
- University Hospital Zurich (CH)
- Corresponding author
- Vollenweider, Franz X.
- Venue
- Nature Reviews Neuroscience
- Published
- 2010-08-18
- Volume
- 11
- Issue
- 9
- Pages
- 642-651
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2068751924
- Semantic Scholar
- d95a57f4b1e3288f21a7dab08ebc2fd5ff10a762
- Cited by
- 723
- References
- 149
- Citations by year
- 2026: 55 · 2025: 75 · 2024: 55 · 2023: 64 · 2022: 53 · 2021: 63 · 2020: 50 · 2019: 35 · 2018: 56 · 2017: 37 · 2016: 48 · 2015: 29 · 2014: 24 · 2013: 18 · 2012: 25
- FWCI
- 3.69
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Keywords
- psychedelics, mood disorders, serotonergic system, glutamatergic system, dissociative anesthetics, LSD, psilocybin, ketamine, neuroplasticity, neural circuits, psychiatric treatment
- MeSH terms
- Animals, Brain, Hallucinogens, Humans, Models, Neurological, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.